Gilead’s remdesivir improves recovery time for COVID-19 patients in peer-reviewed outcomes, according to NIAID


Gilead Sciences Inc.’s antiviral remdesivir has improved recovery time for COVID-19 patients in peer-reviewed data from a study by the National Institute of Allergy and Infectious Diseases, NIAID announced Friday afternoon. In a follow-up to positive preliminary data released last month, NIAID revealed on Friday that peer-reviewed data has shown that patients have recovered enough to be released from hospital in 11 days compared to 14 for those who received a placebo. He also noted that the 14-day mortality rate for those taking the drug had dropped to 7.1% from 11.9% for the placebo group, although NIAID is still studying combinations that could produce a more statistically change. significant – a clinical trial that started on May 8. are studying remdesivir in combination with baricitinib, an anti-inflammatory, to study these results. The Food and Drug Administration has granted Gilead emergency use authorization for the drug to be used on critically ill COVID-19 patients, and Gilead has signed manufacturing agreements. Gilead’s title was down 0.4% in after-hours trading Friday after the announcement; stocks have gained 12.9% so far this year, as the S&P 500
+ 0.23%

fell 8.5%.


Please enter your comment!
Please enter your name here